Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Identifying lung cancer at its earliest stage before symptoms develop allows for earlier treatment and the potential for cure ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) ...

From tennis star Gabriela Dabrowski sharing details of her breast cancer journey to Greg Gumbel and Linda Lavin dying, here ...

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer ...

Ian Smith is reflecting on 'good news' in his battle against terminal lung cancer.The Neighbours legend, who announced his ...

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...